The fourth, eighth, and twelfth laps are sprints, with the first, second, and third skaters to finish gaining, respectively, five points, three points, or one point.
Meanwhile, high Lac SL/tot SL ratio of 47.08 and 48.84 % was gained, respectively.
The corresponding figures in the undiscounted analysis were 0.21, 0.17, €15111, € 7212 per QALY gained, and €90855 per LY gained, respectively.
These relative risks translate in 280 and 173 days gained, respectively.
For men and women aged 70 at initiation of the intervention, the ICER was EUR27,546/QALY gained and EUR19,433/QALY gained, respectively.
These analyses resulted in ICERs of ¥2,049,492 and ¥1,982,802 per QALY gained, respectively, that were similar to the base case.
The 2.5th and 97.5th percentiles were $4,916 and $16,680 per additional QALY gained, respectively (Fig. 1 B).
The 2.5th and 97.5th percentiles were $5,520 and $12,600 per QALY gained, respectively (Fig. 1 A).
Compared to MTX monotherapy, combination therapy resulted in 2.68 and 3.04 discounted life years and QALYs gained, respectively.
Estimated ICERs for denosumab compared with no treatment, alendronate, and risedronate were €3,311, €9,492, and €132 per QALY gained, respectively.
Prophylaxis with posaconazole compared to fluconazole resulted in a gain of 0.19 LYs and 0.17 QALYs corresponding to €24,016 per LY gained and €26,225 per QALY gained, respectively.
